



Bharat Parenterals Limited

Registered Office & Works:

Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Tele : (02667)-251679, 251680, 251669, 99099 28332.

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: U24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

To
The Manager,
Listing Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Date: 08.02.2019

SCRIP CODE: 541096

Dear Sir,

Sub.: Outcome of the Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Bharat Parenterals Limited at its meeting held today has approved the unaudited financial results for the quarter ended on 31st December, 2018.

We enclose herewith Independent Auditor's Limited Review Report and Statement of Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2018.

The Board meeting commenced on 16:00 hours (IST) and concluded at 17:15 hours (IST)

We request you to kindly take the above on record.

Yours Faithfully,

For Bharat Parenterals Limited

Monica Ahir

Company Secretary & Compliance Officer



Encl.: As stated above

Corporate Office:

Shree Avenue, 1st Floor, Above Bank of Baroda, Nr. Amit Nagar Circle, VIP Road, Karelibaug,
Vadodara - 390 022 (Guj.) India. Ph.: (0265) - 3935232, 3935233, 3935234, 99099 84243

Limited Review Report**To the Board of Directors of Bharat Parenterals Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Bharat Parenterals Limited** ("the Company") for the quarter/nine months ended 31st December, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, **C N K & Associates LLP**

Chartered Accountants

Firm Registration no. 101961W/W-100036


Kishor Parikh

(Partner)

Membership No. - 039213

Vadodara, 08th February, 2019

BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelbaug, Vadodara - 390 018

CIN:U24231GJ199ZPLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

Sr.No.	Particulars	Quarter Year Ended			Nine months Ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	9,076.70	4,988.67	3,266.95	17,846.43	9,653.30	13,828.88
	B. Other Income	393.42	219.27	83.26	811.78	616.37	701.40
	Total income	9,470.12	5,207.94	3,350.21	18,658.21	10,269.67	14,530.28
2	Expenses						
	A. Cost of materials consumed	2,868.14	2,586.08	1,952.31	7,425.40	6,187.14	8,881.03
	B. Purchase of Stock-in-Trade	3,684.59	574.35	-	4,411.21	-	-
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	198.26	(414.16)	94.10	(223.93)	(30.43)	(82.52)
	D. Excise duty on sale of goods	-	-	-	-	196.02	196.02
	E. Employee benefit expense	330.06	397.51	243.42	1,126.61	631.34	1,236.76
	F. Finance costs	19.88	36.78	16.14	74.02	68.94	93.93
	G. Depreciation, depletion and amortisation expense	154.83	145.98	115.10	443.58	417.92	557.23
	H. Other Expenses	1,151.66	771.83	463.28	2,534.90	1,465.54	2,270.27
	Total expenses	8,407.42	4,098.37	2,884.35	15,791.79	8,936.48	13,152.74
3	Total profit before tax	1,062.71	1,109.57	465.86	2,866.43	1,333.19	1,377.54
4	Tax expense						
	Current tax	266.48	357.53	-	824.01	-	510.00
	Deferred tax	145.75	313.38	67.05	422.80	67.05	(142.44)
	Total tax expenses	412.23	670.91	67.05	1,246.81	67.05	367.56
5	Net Profit / (loss) for period	650.47	438.66	398.80	1,619.61	1,266.14	1,009.99
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	1.85	1.85	-	5.56	-	7.41
	Income tax relating to Remeasurement of Defined benefit plans	(0.54)	(0.54)	-	(1.62)	-	(2.16)
	Other comprehensive Income for the year, net of taxes	1.31	1.31	-	3.94	-	5.25
7	Total Comprehensive Income for the period	651.79	439.97	398.80	1,623.55	1,266.14	1,015.24
8	Earnings per share						
	Basic (Rs.)	11.35	7.66	6.96	28.27	22.10	17.63
	Diluted (Rs.)	11.35	7.66	6.96	28.27	22.10	17.63

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals".
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara

Date : 08th February, 2019

